论文部分内容阅读
耐甲氧西林金葡菌(MRSA)是院外和院内感染的重要致病菌,近年来已引起国内外许多学者的关注。环丙沙星为一新型氟代喹喏酮衍生物,体外实验证实,该品对MRSA有抗菌活性。本文旨在运用MRSA细菌性心内膜炎动物模型,对国产环丙沙星和去甲基万古霉素进行体内比较性研究,对环丙沙星的药物疗效进行临床前评价,为今后该品用于临床提供理论和实验依据。研究结果表明,经药物治疗三天后,赘生物菌落数明显下降,与实验对照组有显著差别(P<0.01),而治疗组间无差别(P>0.05)。可以预测,环丙沙星可能成为替代去甲基万古霉素治疗MRSA感染的较好品种之一,有待于在治疗人体感染中证实。
Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of nosocomial and nosocomial infections and has attracted the attention of many scholars at home and abroad in recent years. Ciprofloxacin is a new type of fluoroquinolone derivatives, in vitro experiments confirmed that the product has antibacterial activity against MRSA. This article aims to use MRSA bacterial endocarditis animal model of domestic ciprofloxacin and norvancomycin in vivo comparative study of ciprofloxacin drug efficacy of pre-clinical evaluation for the future of the product For clinical to provide theoretical and experimental basis. The results showed that after three days of drug treatment, the number of neoplasm colonies significantly decreased compared with the experimental control group (P <0.01), but no difference between the treatment groups (P> 0.05). Predictably, ciprofloxacin may be one of the better alternatives to demethoxycinomycin for MRSA infection, which needs to be confirmed in the treatment of human infection.